Investigating differences of medications in hospitalized schizophrenia and schizoaffective disorder patients: impact of substance use

References

• Abdel-Baki, A., Thibault, D., Medrano, S., Stip, E., Ladouceur, M., Tahir, R., & Potvin, S. (2020). Long-acting antipsychotic medication as first-line treatment of first-episode psychosis with comorbid substance use disorder. Early Intervention in Psychiatry, 14(1), 69–79. https://doi.org/10.1111/eip.12826
   PubMed Web of Science ®Google Scholar
• Arranz, B., Garriga, M., García-Rizo, C., & San, L. (2018). Clozapine use in patients with schizophrenia and a comorbid substance use disorder: A systematic review. European Neuropsychopharmacology, 28(2), 227–242. https://doi.org/10.1016/j.euroneuro.2017.12.006
   PubMed Web of Science ®Google Scholar
• Baghai, T. C., & Möller, H.-J. (2008). Electroconvulsive therapy and its different indications. Dialogues in Clinical Neuroscience, 10(1), 105. https://doi.org/10.31887/DCNS.2008.10.1/tcbaghai
   PubMedGoogle Scholar
• Bogers, J. P., Schulte, P. F., Van Dijk, D., Bakker, B., & Cohen, D. (2016). Clozapine underutilization in the treatment of schizophrenia: How can clozapine prescription rates be improved? Journal of Clinical Psychopharmacology, 36(2), 109–111. https://doi.org/10.1097/JCP.0000000000000478
   PubMed Web of Science ®Google Scholar
• Bozzatello, P., Bellino, S., & Rocca, P. (2019). Predictive factors of treatment resistance in first episode of psychosis: A systematic review. Frontiers in Psychiatry, 10, 67. https://doi.org/10.3389/fpsyt.2019.00067
   PubMed Web of Science ®Google Scholar
• Crockford, D., & Addington, D. (2017). Canadian schizophrenia guidelines: Schizophrenia and other psychotic disorders with coexisting substance use disorders. The Canadian Journal of Psychiatry, 62(9), 624–634. https://doi.org/10.1177/0706743717720196
   PubMed Web of Science ®Google Scholar
• Dixon, L. (1999). Dual diagnosis of substance abuse in schizophrenia: Prevalence and impact on outcomes. Schizophrenia Research, 35(suppl. 1), S93–S100. https://doi.org/10.1016/S0920-9964(98)00161-3
   PubMedGoogle Scholar
• Fenton, W. S., Blyler, C. R., & Heinssen, R. K. (1997). Determinants of medication compliance in schizophrenia: Empirical and clinical findings. Schizophrenia Bulletin, 23(4), 637–651. https://doi.org/10.1093/schbul/23.4.637
   PubMed Web of Science ®Google Scholar
• Foglia, E., Schoeler, T., Klamerus, E., Morgan, K., & Bhattacharyya, S. (2017). Cannabis use and adherence to antipsychotic medication: A systematic review and meta-analysis. Psychological Medicine, 47(10), 1691–1705. https://doi.org/10.1017/S0033291717000046
   PubMed Web of Science ®Google Scholar
• Ghoreishi, A., Kabootvand, S., Zangani, E., Bazargan-Hejazi, S., Ahmadi, A., & Khazaie, H. (2015). Prevalence and attributes of criminality in patients with schizophrenia. Journal of Injury & Violence Research, 7(1), 7. https://doi.org/10.5249/jivr.v7i1.635
   PubMedGoogle Scholar
• Hachtel, H., Harries, C., Luebbers, S., & Ogloff, J. R. (2018). Violent offending in schizophrenia spectrum disorders preceding and following diagnosis. Australian & New Zealand Journal of Psychiatry, 52(8), 782–792. https://doi.org/10.1177/0004867418763103
   PubMed Web of Science ®Google Scholar
• Hunt, G. E., Large, M. M., Cleary, M., Lai, H. M. X., & Saunders, J. B. (2018). Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990-2017: Systematic review and meta-analysis. Drug and Alcohol Dependence, 191, 234–258. https://doi.org/10.1016/j.drugalcdep.2018.07.011
   PubMed Web of Science ®Google Scholar
• Jørgensen, K. B., Nordentoft, M., & Hjorthøj, C. (2018). Association between alcohol and substance use disorders and psychiatric service use in patients with severe mental illness: A nationwide Danish register-based cohort study. Psychological Medicine, 48(15), 2592–2600. https://doi.org/10.1017/S0033291718000223
   PubMed Web of Science ®Google Scholar
• Karabekiroglu, A., Pazvantoglu, O., Karabekiroglu, K., Boke, O., & Korkmaz, I. Z. (2016). Associations with violent and homicidal behaviour among men with schizophrenia. Nordic Journal of Psychiatry, 70(4), 303–308. https://doi.org/10.3109/08039488.2015.1109139
   PubMed Web of Science ®Google Scholar
• Karpov, B., Joffe, G., Aaltonen, K., Oksanen, J., Suominen, K., Melartin, T., Baryshnikov, I., Koivisto, M., Heikkinen, M., & Isometsa, E. T. (2018). Self-reported treatment adherence among psychiatric in- and outpatients. Nordic Journal of Psychiatry, 72(7), 526–533. https://doi.org/10.1080/08039488.2018.1538387
   PubMed Web of Science ®Google Scholar
• Kessler, T., & Lev-Ran, S. (2019). The association between comorbid psychiatric diagnoses and hospitalization-related factors among individuals with schizophrenia. Comprehensive Psychiatry, 89, 7–15. https://doi.org/10.1016/j.comppsych.2018.12.004
   PubMed Web of Science ®Google Scholar
• Khokhar, J. Y., Henricks, A. M., Sullivan, E. D. K., & Green, A. I. (2018). Unique effects of clozapine: A pharmacological perspective. Advances in Pharmacology (San Diego, Calif.), 82, 137–162. https://doi.org/10.1016/bs.apha.2017.09.009
   PubMedGoogle Scholar
• Koola, M. M., Wehring, H. J., & Kelly, D. L. (2012). The potential role of long-acting injectable antipsychotics in people with schizophrenia and comorbid substance use. Journal of Dual Diagnosis, 8(1), 50–61. https://doi.org/10.1080/15504263.2012.647345
   PubMed Web of Science ®Google Scholar
• Krause, M., Huhn, M., Schneider-Thoma, J., Bighelli, I., Gutsmiedl, K., & Leucht, S. (2019). Efficacy, acceptability and tolerability of antipsychotics in patients with schizophrenia and comorbid substance use. A systematic review and meta-analysis. European Neuropsychopharmacology, 29(1), 32–45. https://doi.org/10.1016/j.euroneuro.2018.11.1105
   PubMed Web of Science ®Google Scholar
• Lay, B., Kawohl, W., & Rossler, W. (2019). Predictors of compulsory re-admission to psychiatric inpatient care. Frontiers in Psychiatry, 10, 120. https://doi.org/10.3389/fpsyt.2019.00120
   PubMed Web of Science ®Google Scholar
• Machielsen, M. W., Veltman, D. J., van den Brink, W., & de Haan, L. (2018). Comparing the effect of clozapine and risperidone on cue reactivity in male patients with schizophrenia and a cannabis use disorder: A randomized fMRI study. Schizophrenia Research, 194(4), 32–38. https://doi.org/10.1016/j.schres.2017.03.030
   PubMedGoogle Scholar
• Malat, J., & Kahn, D. A. (2011). Clinical barriers to effective pharmacotherapy in co-occurring psychiatric and substance use disorders. Journal of Psychiatric Practice, 17(5), 360–367. https://doi.org/10.1097/01.pra.0000405367.82419.29
   PubMed Web of Science ®Google Scholar
• Marcus, S. C., Zummo, J., Pettit, A. R., Stoddard, J., & Doshi, J. A. (2015). Antipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital discharge. Journal of Managed Care & Specialty Pharmacy, 21(9), 754–769. https://doi.org/10.18553/jmcp.2015.21.9.754
   PubMed Web of Science ®Google Scholar
• Mauri, M. C., Volonteri, L. S., De Gaspari, I. F., Colasanti, A., Brambilla, M. A., & Cerruti, L. (2006). Substance abuse in first-episode schizophrenic patients: A retrospective study. Clinical Practice and Epidemiology in Mental Health, 2(1), 4. https://doi.org/10.1186/1745-0179-2-4
   PubMedGoogle Scholar
• McHugh, M. J., McGorry, P. D., Yung, A. R., Lin, A., Wood, S. J., Hartmann, J. A., & Nelson, B. (2017). Cannabis-induced attenuated psychotic symptoms: Implications for prognosis in young people at ultra-high risk for psychosis. Psychological Medicine, 47(4), 616–626. https://doi.org/10.1017/S0033291716002671
   PubMed Web of Science ®Google Scholar
• Morrens, M., Dewilde, B., Sabbe, B., Dom, G., De Cuyper, R., & Moggi, F. (2011). Treatment outcomes of an integrated residential programme for patients with schizophrenia and substance use disorder. European Addiction Research, 17(3), 154–163. https://doi.org/10.1159/000324480
   PubMed Web of Science ®Google Scholar
• O’Connell, J., Sunwoo, M., McGorry, P., & O’Donoghue, B. (2019). Characteristics and outcomes of young people with substance induced psychotic disorder. Schizophrenia Research, 206, 257–262. https://doi.org/10.1016/j.schres.2018.11.007
   PubMed Web of Science ®Google Scholar
• Rao, K. N., George, J., Sudarshan, C., & Begum, S. (2017). Treatment compliance and noncompliance in psychoses. Indian Journal of Psychiatry, 59(1), 69. https://doi.org/10.4103/psychiatry.IndianJPsychiatry_24_17
   PubMed Web of Science ®Google Scholar
• Sanghani, S. N., Marsh, A. N., John, M., Soman, A., Lopez, L. V., Young, Y. A., & Russ, M. J. (2017). Characteristics of patients involved in physical assault in an acute inpatient psychiatric setting. Journal of Psychiatric Practice, 23(4), 260–269. https://doi.org/10.1097/PRA.0000000000000238
   PubMed Web of Science ®Google Scholar
• SanSegundo, M. S., Ferrer-Cascales, R., Bellido, J. H., Bravo, M. P., Oltra-Cucarella, J., & Kennedy, H. G. (2018). Prediction of violence, suicide behaviors and suicide ideation in a sample of institutionalized offenders with schizophrenia and other psychosis. Frontiers in Psychology, 9, 1385. https://doi.org/10.3389/fpsyg.2018.01385
   PubMed Web of Science ®Google Scholar
• Schultze-Lutter, F., Michel, C., Ruhrmann, S., & Schimmelmann, B. G. (2018). Prevalence and clinical relevance of interview-assessed psychosis-risk symptoms in the young adult community. Psychological Medicine, 48(7), 1167–1178. https://doi.org/10.1017/S0033291717002586
   PubMed Web of Science ®Google Scholar
• Short, T., Thomas, S., Mullen, P., & Ogloff, J. R. (2013). Comparing violence in schizophrenia patients with and without comorbid substance-use disorders to community controls. Acta psychiatrica Scandinavica, 128(4), 306–313. https://doi.org/10.1111/acps.12066
   PubMed Web of Science ®Google Scholar
• Smelson, D. A., Dixon, L., Craig, T., Remolina, S., Batki, S. L., Niv, N., & Owen, R. (2008). Pharmacological treatment of schizophrenia and co-occurring substance use disorders. CNS Drugs, 22(11), 903–916. https://doi.org/10.2165/00023210-200822110-00002
   PubMed Web of Science ®Google Scholar
• Starr, H. L., Bermak, J., Mao, L., Rodriguez, S., & Alphs, L. (2018). Comparison of long-acting and oral antipsychotic treatment effects in patients with schizophrenia, comorbid substance abuse, and a history of recent incarceration: An exploratory analysis of the PRIDE study. Schizophrenia Research, 194, 39–46. https://doi.org/10.1016/j.schres.2017.05.005
   PubMed Web of Science ®Google Scholar
• Stompe, T., Ritter, K., & Schanda, H. (2018). Patterns of substance abuse in offenders with schizophrenia—Illness-related or criminal life-style? Frontiers in Psychiatry, 9. https://doi.org/10.3389/fpsyt.2018.00233
   Google Scholar
• Tekin Uludag, Y., & Gulec, G. (2016). Prevalence of substance use in patients diagnosed with schizophrenia. Noro Psikiyatri Arsivi, 53(1), 4–11. https://doi.org/10.5152/npa.2015.8827
   PubMedGoogle Scholar
• Thomsen, K. R., Thylstrup, B., Pedersen, M. M., Pedersen, M. U., Simonsen, E., & Hesse, M. (2018). Drug-related predictors of readmission for schizophrenia among patients admitted to treatment for drug use disorders. Schizophrenia Research, 195, 495–500. https://doi.org/10.1016/j.schres.2017.09.026
   PubMed Web of Science ®Google Scholar
• Ural, C., Öncü, F., Belli, H., & Soysal, H. (2013). Violent behavior variables among patients with schizophrenia under forensic psychiatric process: A case-control study. Turk Psikiyatri Dergisi = Turkish Journal of Psychiatry, 24(1), 17–24. https://www.turkpsikiyatri.com/Data/UnpublishedArticles/e3he0d.pdf
   PubMed Web of Science ®Google Scholar
• Witt, K., van Dorn, R., & Fazel, S. (2013). Risk factors for violence in psychosis: Systematic review and meta-regression analysis of 110 studies. PLoS One, 8(2), e55942. https://doi.org/10.1371/journal.pone.0055942
   PubMed Web of Science ®Google Scholar
• Ziedonis, D. M., Smelson, D., Rosenthal, R. N., Batki, S. L., Green, A. I., Henry, R. J., Montoya, I., Parks, J., & Weiss, R. D. (2005). Improving the care of individuals with schizophrenia and substance use disorders: Consensus recommendations. Journal of Psychiatric Practice, 11(5), 315. https://doi.org/10.1097/00131746-200509000-00005
   PubMedGoogle Scholar